US Patent Litigations are now available. Check here

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 17, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3324956Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor1
EP3407880Aug 17, 2022Neurodevelopmental Disorder Therapy1